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CHAPTER ONE
LITERATURE REVIEW
Statement of the Problem
Peripheral Neuropathy (PN) is characterized as damage or injury to the peripheral
nervous system (PNS) and is a hallmark of metabolic syndrome (MetS). Our lab has previously
published that ER stress induced by western diet (WD) containing high fat, high sucrose, and
cholesterol, leads to the structural and functional damage of afferent sensory nerves triggering
pain and neuropathy (Gavini et al., 2018). Additionally, the activation of Liver X Receptors
(LXRs) using the synthetic agonist GW3965, protects mice from WD-induced painful
neuropathy (Gavini et al., 2018). LXRs are of interest due to their known crucial role in the
regulation of lipid homeostasis, membrane phospholipid remodeling, and inflammation
identified in metabolically active tissues such as the liver (Calkin & Tontonoz, 2012; Rong et al.,
2013; Rong et al., 2015). Their cellular and molecular roles in the PNS and pain in MetS remains
to be fully elucidated.
The dorsal root ganglia (DRG) located in the PNS, contains the afferent nociceptive
neuronal cell bodies. They carry sensory messages to the central nervous system from peripheral
nerves and mediate neuropathic pain (NP). Here, I confirm that LXR target genes are expressed
in the DRG, and I provide potential mechanisms underlying LXR to improve NP in WD-fed
mouse models, including cholesterol transport, membrane lipid composition, and neuronal
prostaglandin synthesis (Figure 1). Overall, we unmasked that Lysophosphatidylcholine
acyltransferase 3 (LPCAT3) is regulated by the activation of LXR. Interestingly, by modulating
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arachidonic acid’s insertion into the cell membrane, LPCAT3 impacts prostaglandin production
and membrane lipid composition, both being disturbed in the sensory neurons of obese mice.
Using the LXR synthetic agonist and transgenic mice, we performed ex vivo studies to confirm
that the LXR agonist upregulates LPCAT3, decreases prostaglandin production, and modulates
lipid composition in DRG sensory neurons.

Figure 1. Neuronal LXR Regulates Genes that Control Lipid Balance between the Plasma
Membrane and the Cytosol. Activation of LXR target genes regulate lipid and cholesterol
homeostasis including LPCAT3, ABCA1, IDOL, and LDLR. ABCA1 is responsible for cellular
cholesterol efflux, while LDLR is involved in cholesterol influx. Inducible degrader of the lowdensity lipoprotein (LDL) receptor (IDOL) is an inducible degrader of LDLR and suppresses its
activity. LPCAT3 has been demonstrated to be involved in the modulation of membrane lipid
composition and fluidity, especially in lipid rafts. Its role in lipid remodeling has also been
determined to reduce the bioavailability of the polyunsaturated fatty acid arachidonic acid, which
is a precursor to the prostaglandin synthesis pathway. It is known that changes in lipid raft
composition modulate synaptic signaling and neuronal excitability, and prostaglandin production
modulates these signaling pathways in an autocrine manner to sensitize neurons leading to pain.
Activation of LXR may improve neuronal lipid dysfunction, resulting in pain improvement.
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Neuropathic Pain
Epidemiology
Chronic NP is a major contributor to the global burden of disease, causing major
suffering and a reduced quality of life (Doth, Hansson, Jensen, & Taylor, 2010; B. H. Smith
& Torrance, 2012). Diagnostic tools are available for NP; however, it is considered to be
underdiagnosed as classification of this condition has only been recently developed
(Finnerup et al., 2013). The International Association for the Study of Pain (IASP) defines
NP as “pain caused by a lesion or disease of the somatosensory nervous system,” which
differs from nociceptive pain described as “pain through the activation of nociceptors in
non-neural tissues by actual or threatened tissue injury” (Raja et al., 2020). A more recently
added term, nociplastic pain, is defined as “pain that arises from altered nociception despite
no clear evidence of actual threatened tissue damage causing the activation of peripheral
nociceptors or evidence for disease or lesion of the somatosensory system causing the
pain,” (Raja et al., 2020).
Approximately 30% of patients with NP experience a 30% reduction in pain
symptoms with pain management (Finnerup et al., 2015). Pharmacological therapies are
available to ease symptoms, such as gabapentinoids, opioids, and antidepressants (Haanpää
et al., 2010). While effective for short-term relief of symptoms, these drug therapies often
come with addiction and lack of effectiveness after chronic use. Gabapentinoids, and
tricyclic antidepressants, which are considered first-line agents for NP management, can
cause weight gain, and sedative effects that increase the risk of falls, respectively (Backonja
& Galer, 1998; Haanpää et al., 2010). Opioids, while not a primary therapeutic option, raise
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concerns regarding abuse or misuse due to their highly addictive nature (Furlan, Reardon,
Weppler, & Group, 2010; Nuckols et al., 2014).
The Nociceptive Pathway
Nociception is the detection of thermal, mechanical, or chemical stimuli by
nociceptive peripheral nerve fibers (Jessell, Kandel, & Schwartz, 2000). The DRG contains
the cell bodies of nociceptive fibers with pseudo-unipolar axons innervating peripheral
tissues and directly carrying sensory signals to the central nervous system (Figure 2)
(Basbaum, Bautista, Scherrer, & Julius, 2009). Damage to nociceptive fibers (particularly
Aβ, Aδ, and C fibers), alters their transmission of sensory signals due to compromised ion
channel function (Colloca et al., 2017). These nociceptive fibers respond to different stimuli
based on their biophysical properties that enable them to selectively detect and respond to
normal or potentially damaging sensations. Aβ fibers are large diameter, rapid conducting
fibers that respond to non-noxious mechanical stimuli, while medium diameter myelinated
Aδ fibers respond to noxious mechanical stimuli (Figure 2) (Basbaum, Bautista, Scherrer,
& Julius, 2009). A second class of nociceptive fibers include small diameter unmyelinated
C fibers that respond to slow and poorly localized pain, including noxious heat and
chemical stimuli. They are also known to express the sodium channel Nav1.8, which has
been utilized in transgenic mouse models as a sensory neuron marker for pain studies
(Figure 2) (Basbaum et al., 2009).
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Figure 2. Nociceptive Afferent Nerve Fibers and their Stimuli. The DRG contains the cell
bodies of sensory neurons in the nociceptive pathway. Aβ fibers are responsible for detecting
non-noxious mechanical stimuli. Aδ fibers are responsible for noxious (painful) mechanical
stimuli, and unmyelinated C fibers detect noxious heat and chemical stimuli. Signals are
transmitted to the sensory neuron cell bodies of the DRG, then transmitted to the spinal cord and
the brain where they are processed and recognized as pain. In the nociceptive pain phenotype,
individuals experience nerve injury that results in hypersensitivity to these sensory stimuli,
resulting in NP. Figure is adapted from Stahl’s Essential Psychopharmacology (Stahl & Muntner,
2013).
Metabolic Syndrome and Peripheral Neuropathy
PN is an umbrella term for the broad range of disorders affecting the function of the PNS
as a result of nerve injury. Of peripheral neuropathies, distal sensory polyneuropathy (DSP) is
one of the most prevalent neurological disorders, resulting in distal sensory loss and pain (Barrell
& Smith, 2019). The prevalence of DSP is owed to the increasing diabetic and obese population,
with 50% of cases accounting for diabetic individuals and 40% of cases associated with
prediabetes and MetS (Gregg et al., 2004; Tesfaye et al., 2011). High circulating glucose is
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known to contribute to peripheral nerve damage, however, there is a body of evidence showing
that PN can occur before the onset of diabetes in many obese and MetS patients, distinguishing
between cryptogenic sensory peripheral neuropathy (CSPN) associated with MetS and diabetic
peripheral neuropathy (DPN) (Kazamel, Stino, & Smith, 2021; Stino & Smith, 2017).
MetS is defined as a cluster of conditions that include hypertension, hyperglycemia,
abdominal obesity, and dyslipidemia (abnormal triglyceride levels and reduced high-density
lipoprotein levels) (Cornier et al., 2008; Stino & Smith, 2017). As mentioned, in many cases,
glucose management fails to reduce or improve NP (B. Callaghan & Feldman, 2013; B. C.
Callaghan et al., 2016). In rat models of MetS and diet-induced obesity, studies have found that
neuronal dysfunction can even occur in nonhyperglycemic animals, suggesting that the
manifestation of PN is not dependent on hyperglycemia alone (Davidson, Coppey, Calcutt,
Oltman, & Yorek, 2010; Oltman et al., 2005).
The exact mechanisms behind MetS-associated PN are still being investigated by our
laboratory and others as several non-glucose pathways have been linked to NP. In vitro studies of
the DRG have demonstrated that MetS leads to mitochondrial dysfunction, oxidative and
endoplasmic reticulum (ER) stress, insulin resistance, neuroinflammation and compromised
neurotrophic factors (Figure 3) (B. Callaghan & Feldman, 2013; Vincent, Callaghan, Smith, &
Feldman, 2011). It is still unclear how these pathways disrupt the nociceptive pathway and
neuronal distal retraction. The associated lipid and glucose dysregulation lead to the production
of reactive oxygen species (ROS), which leads to mitochondrial dysfunction and ER stress in
neurons (Figure 3) (Hinder, Vincent, Burant, Pennathur, & Feldman, 2012; Hinder,
Vivekanandan-Giri, McLean, Pennathur, & Feldman, 2013). Excess glucose and fatty acids as a
result of MetS, produces excess electron donors during the process of oxidative phosphorylation,
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and in return, increases ROS formation (Fernyhough, 2015; Vincent et al., 2011). This reduces
mitochondrial viability and function, as well as overwhelms antioxidative processes, which, as a
result, causes neuronal hyperexcitability and injury (Figure 3) (Fernyhough, 2015).
Neuronal oxidative stress also leads to the activation of nuclear factor kappa-light- chainenhancer of activated B cells (NFκB) by Jun N-terminal kinases (JNK) and inhibition of nuclear
factor Kb kinase B (IκKB), triggering the release of pro-inflammatory cytokines and chemokines
that further exacerbate neuronal injury and inflammation (Figure 3) (B. Callaghan &
Feldman,2013; Odegaard & Chawla, 2013; Stavniichuk et al., 2014). Collectively, these
imbalances are suggested to be causes of sensory nerve damage. Interestingly, recent human and
rodent studies highlighted the importance of lipid pathways in relationship to PN. Currently,
numerous studies focus on peripheral nerves of diet-induced obese rodent models as described
below, together with nerve studies from obese patients in RNA sequencing experiments and
identify lipid pathways dysregulated together with circulating lipid correlating with pain
involving LXR as discussed in detail below ( O'Brien, Sakowski, & Feldman, 2014).
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Figure 3. Signaling Pathways Affected by MetS Contributing to CSPN. Hyperglycemia and
hyperlipidemia due to nutrient excess induce cellular oxidative stress pathways that lead to
mitochondrial dysfunction and ER stress. While they directly contribute to CSPN and associated
nerve damage, these characteristics aggravate insulin resistance and contribute to tissue
inflammation. Leukocyte recruitment, pro-inflammatory chemokines, and NFκB activation via
JNK and IKKb also contribute to inflammatory signaling and the further exacerbation of insulin
resistance. Together, these destructive pathways associated with MetS contribute to the
pathogenesis of CSPN and nerve degeneration. This figure is adapted from B. Callaghan &
Feldman, 2013.
Murine Models for Metabolic Syndrome and Peripheral Neuropathy
Transgenic mouse models with compromised leptin signaling are often used to study PN
in the context of MetS and type 2 diabetes. Leptin is a hormone involved in controlling appetite
by hypothalamic signaling, and mutations in mouse models that develop a leptin deficiency
(ob/ob mice) or a leptin receptor knockout (db/db mice) result in an increase in appetite and the
development of MetS components, such as obesity, hyperglycemia, and insulin intolerance
(O'Brien et al., 2014). Db/db mice develop type 2 diabetes at 4 weeks of age, and develop
mechanical allodynia (pain from mechanical stimuli that does not normally cause pain) as well as
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thermal hyperalgesia (increased sensitivity to thermal stimuli that normally causes pain) at 12
weeks of age (Cheng, Dauch, Hayes, Hong, & Feldman, 2009; Raja et al., 2020). Ob/ob mice,
more often used as a model of MetS, develop characteristics of mild type 2 diabetes with chronic
hyperglycemia. By 11 weeks of age, they display symptoms of nerve dysfunction and similar
pain behavior as db/db mice (Drel et al., 2006).
Because prediabetes is a key factor in the pathogenesis of CSPN, WD-fed mice are often
used as a mouse model for diet-induced obesity and to study PN under these prediabetic
conditions. The gradual onset of metabolic dysfunction is physiologically relevant as opposed to
db/db and ob/ob mice that develop type 2 diabetes at an early age, making the study of CSPN
difficult due to the short time frame of a prediabetic phenotype (O'Brien et al., 2014). WD-fed
mice develop the classic characteristics of obesity (Figure 4J,K) and MetS, including glucose
intolerance and insulin resistance (Figure 4B,C). WD-fed mice also have elevated blood
triglycerides, cholesterol, leptin, and insulin levels (Figure 4D,E,F,G). This WD feeding
paradigm causes mechanical allodynia and thermal hyperalgesia which are two defining
characteristics of NP (Figure 4H,I). Apart from the NP phenotype, WD-fed mice develop a loss
of nerve fibers innervating the skin (Figure 4L), demonstrating peripheral nerve injury.
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Figure 4. WD-Fed Mice as a Model for MetS-Associated CSPN and Neuropathic Pain. (A)
Body weights taken over a period of 12 weeks of NC and WD-fed mice. (B) Glucose tolerance
test. (C) Insulintolerance test. (D) Blood triglyceride, (E) cholesterol, (F) Leptin, and (G) insulin
levels. (H) VonFrey behavioral test for mechanical allodynia. (I) Thermal behavioral test for
hyperalgesia. (J) Body size of mice fed NC or WD for 12 weeks. (K) Livers of mice on NC or
WD for 12 weeks. (L) Intraepidermal nerve fibers in NC- vs WD-fed mice (blue, dermis; red,
nerve fibers).
Liver X Receptors
Liver X Receptors (LXRs) are nuclear transcription factors that play a pivotal role in
lipid homeostasis and metabolism (Laurencikiene & Rydén, 2012). The LXR isoforms,
LXRα and LXRβ, form a heterodimeric complex with Retinoid X Receptor (RXR) when
bound to an LXRE (LXR response element) in regulatory regions of target DNA sequences
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(Calkin & Tontonoz, 2012). This response element contains the replicated sequence
AGGTCA that is separated by four nucleotides (DR4), serving as a functional role in
determining LXR binding to target DNA sequences. As a master regulator of lipid
homeostasis, oxysterols, the oxidized derivatives of cholesterol, are ligands for LXRs. As
these receptors are considered pharmaceutical targets due to their role in lipid metabolism,
synthetic ligands have also been developed as tools in biomedical research for in vivo and
in vitro studies, including T091317 andGW3965 (Collins et al., 2002; Schultz et al., 2000).
Upon ligand binding to LXR, the heterodimeric complex LXR/RXR changes conformation,
leading to the recruitment of co-activators and therelease of co-repressors to activate target
gene transcription (Calkin & Tontonoz, 2012; Glass & Rosenfeld, 2000). LXRα is
dominantly expressed in metabolically active tissues, such as the liver, small intestine,
adipose tissue, kidney, and macrophages, while LXRβ is ubiquitously expressed (Calkin &
Tontonoz, 2012; Zhao & Dahlman-Wright, 2010).
When intracellular cholesterol concentrations increase, the oxidized ligands activate
LXRs, thus, inducing the transcription of target genes that promote cholesterol efflux, such as
ABCA1, ABCG1, and ApoE (Zelcer, Hong, Boyadjian, & Tontonoz, 2009). Previous studies
have shown that ligand activation of LXR decreases LDLR expression and upregulates IDOL
upon detection of LDL, indicating that not only does LXR promote cholesterol efflux through its
target genes, but also by suppressing influx (Courtney & Landreth, 2016). Altogether, these
target genes modulate lipid and cholesterol homeostasis, which, in turn, mitigates ER stress
associated with lipid dysfunction. While the role of LXRs is well understood in metabolic
tissues, the mechanisms of LXRs in the PNS is yet to be fully understood. Literature has
demonstrated the enrichment of the LXR/RXR pathway in the sciatic nerves of db/db and ob/ob
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mice when studying the progression of PN (McGregor et al., 2018). In db/db mice, expression of
genes in the LXR/RXR pathway are largely downregulated during the early onset of PN,
however, the expression of genes in this pathway demonstrate a 2-fold increase at 24 weeks of
age as PN progresses. Similarly, ob/ob mice maintain this upregulation of genes in the
LXR/RXR pathway at earlier stages of PN (McGregor et al., 2018).
In recent studies, LXR has been demonstrated to have protective effects against ROSs in
the sciatic nerve by upregulating antioxidative enzymes in Schwann cells and reducing ROS
production (Hichor et al., 2018). Our lab published that LXR activation with the synthetic
agonist GW3965 protected sensory neurons from obesity-induced ER stress resulting in a
decrease in pain (Gavini et al., 2018). This effect is eliminated in sensory neuron LXR knockout
models, demonstrating that the agonist acts via LXR to improve pain (Gavini et al., 2018). The
molecular mechanism linking LXR activation in neurons and the decrease in pain in obese rodent
models is still unclear. We hypothesize that LXR controls intracellular neuronal cholesterol
levels that indirectly may be involved in decreasing prostaglandin production, modulating lipid
raft formation. We predict that the target gene LPCAT3 is a major actor in this process.
LPCAT3 and Membrane Lipid Remodeling
LPCAT3, is an ER membrane protein regulated by LXR, more specifically, by the
isoform LXRa (Demeure et al., 2011; Wang & Tontonoz, 2019). LPCAT3 is abundantly
expressed and well-characterized in human and murine metabolic tissues such as the liver,
intestine, and adipose tissue (Wang & Tontonoz, 2019). It is known that LPCAT3 is involved in
the process of modulating lipogenesis, very low-density lipoprotein (VLDL) secretion, and
adipogenesis through the manipulation of membrane phospholipids, thus, modulating membrane
composition and fluidity as well as downstream-signaling processes (Rong et al., 2013).
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Membrane phospholipids are highly dynamic species that undergo remodeling processes
after de novo synthesis via the Kennedy pathway. This remodeling process, also known as the
Lands cycle, involves a series of reacylation and deacylation reactions that result in removing
and replacing fatty acyl chains of phospholipid species (Demeure et al., 2011).
Lysophosphatidylcholine acyltransferases (LPCATs) are involved in the reacylation mechanism
by incorporating fatty acyl chains at the sn-2 position to synthesize various phospholipid species
(Demeure et al., 2011). In hepatocytes, LPCAT3 catalyzes the incorporation of polyunsaturated
fatty acids such as arachidonic acid (20:4) and linoleic acid (18:2), into membrane
phosphatidylcholine species at the sn-2 position (Rong et al., 2013). While both arachidonic acid
and linoleic acid incorporation under the control of LPCAT3 has been demonstrated, studies
report that LPCAT3 preferentially regulates arachidonic acid insertion in metabolic tissues.
Specifically, in LPCAT3-deficient mice, the reduction in arachidonate-containing phospholipid
species is most prominent, while changes in linoleate species were negligible (HashidateYoshida et al., 2015). The abundance of polyunsaturated phospholipids allows for sterol
regulatory element-binding protein (SREBP-1c) activity, which facilitates its transport from the
endoplasmic reticulum (ER) for proteolytic cleavage in the Golgi. This process promotes VLDL
lipidation and upregulates certain lipogenic target genes, such as fatty acid synthase (FASN) and
stearoyl-CoA desaturase-1 (Wang & Tontonoz, 2018, 2019). In Liver-specific Lpcat3-/- mice,
LPCAT3 deficiency reduces membrane arachidonoyl phospholipids as well as decreases
membrane mobility, hindering VLDL packaging and secretion (Lee & Tontonoz, 2015).
LPCAT3 and Inflammation
Recent investigations have focused on the mechanisms of the anti-inflammatory effects
induced by LXRs. As a key regulator of cholesterol and fatty acid metabolism, LXR-dependent
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activation of LPCAT3 has been shown to reduce hepatic ER stress and inflammation as a result
of lipid overload in the context of obesity and MetS . The liver-specific knockout of LPCAT3 of
ob/ob mice, a genetic model of obesity, induced the expression of ER stress markers
accompanied by an increase in the phosphorylation of PERK and eIF2a, indicating activation of
the unfolded protein response initiated by lipid dysfunction. Additionally, this knockout elevates
the expression of pro-inflammatory cytokines such as MCP-1, TNF-a, and IL-1B, with similar
observations in db/db mice (Figure 5) (Rong et al., 2013). These effects, however, are
ameliorated in wild-type mice overexpressing LPCAT3, suggesting its regulatory role in
inflammation associated with metabolic diseases. Mechanistically, this tissue-specific knockout
reduces the number of phosphatidylcholine species containing arachidonic and linoleic acid,
suggesting that this membrane remodeling counteracts lipid-induced ER stress and inflammation
(Figure 5). With arachidonic acid incorporation in the membrane, this decreases the intracellular
bioavailability of the fatty acid for downstream pathways.
Understanding the effect of fatty acid remodeling by the LXR activation of LPCAT3 is
crucial to understanding the NP pathway, as prostaglandin synthesis in peripheral sensory
neurons modulates the development of inflammation and pain phenotypes. We hypothesize that
LXRs regulate lipid homeostasis in sensory neurons to, not only modulate ER stress-induced
lipid overload, but to reduce the bioavailability of arachidonic acid to synthesize prostaglandins,
both in relationship to NP in obesity.
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Figure 5. Modulation of Membrane Phospholipids by LPCAT3. In hepatocytes, LPCAT3
drives the incorporation of polyunsaturated fatty acids (notably linoleic and arachidonic acid)
into membrane phospholipids upon LXR activation. The increase inconcentration of unsaturated
fatty acids decreases the availability of intracellular pro-inflammatory lipids, reduces lipidinduced ER stress, and modulates downstream inflammatory pathways. This figure is from Rong
et. al., 2013.
Prostaglandins
The role of inflammation is classically associated with the response to tissue damage or
infection, as the inflammatory response plays a role in various metabolic and
immunosuppressing disease states (Ellis & Bennett, 2013). With this response, prostaglandins
are key mediators in the development of inflammation, and, ultimately, the exacerbation of pain.
(Ricciotti & FitzGerald, 2011). These bioactive lipids, termed eicosanoids, are derived from the
membrane-bound polyunsaturated fatty acid, arachidonic acid (Jang, Kim, & Hwang, 2020). In
acute inflammatory conditions, before to the infiltration of immune cells and leukocyte
recruitment, arachidonic acid is released from the plasma membrane by cytosolic phospholipase
A2 (cPLA2) and metabolized by both isoforms of cyclooxygenase (COX-1; COX-2) to
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synthesize Prostaglandin H2 (PGH2) (Figure 6) (Ricciotti & FitzGerald, 2011). While both
isoforms contribute to inflammation, COX-1 is constitutively expressed in most cell types,
serving as a dominant source of prostaglandins that maintains homeostatic functions such as
gastric epithelial cryoprotection while COX-2 is inducible by inflammatory stimuli, hormones,
and growth factors (Ricciotti & FitzGerald, 2011). While prostaglandins are ubiquitously
produced, specific cell types generate one or two bioactive products, reliant on the conversion of
PGH2 by differentially expressed tissue-specific synthases that produce terminal, active
eicosanoids (Figure 6) (Ricciotti & FitzGerald, 2011).
In the PNS, prostaglandins were first characterized in chicken DRG, with prostaglandin
D2 (PGD2) and prostaglandin E2 (PGE2) being the two subtypes widely produced from supplied
arachidonic acid (Figure 6) (Vesin & Droz, 1991). They demonstrated that PGD2 is mainly
synthesized in primary somatosensory neurons, whereas PGE2 is produced in DRG capsules and
surrounding meninges (Vesin, Barakat-Walter, & Droz, 1991). Further investigations utilizing rat
sensory neurons revealed the expression of Prostaglandin E2 synthase (PTGES) and
prostaglandin D2 synthase (PTGDS) in rat DRG and spinal cord under inflammatory conditions,
mediated by COX-2 (Grill, Heinemann, Hoefler, Peskar, & Schuligoi, 2008; Schuligoi, Ulcar,
Peskar, & Amann, 2003). While these investigations confirm the presence of prostaglandin
synthesis in the PNS, the differential expression of the cyclooxygenase isoforms is widely
debated. In early investigations, COX-1 was detected in small-to-medium sized rat DRG
neurons, where COX-2 was absent (Willingale, Gardiner, McLymont, Giblett, & Grubb, 1997).
In a mouse collagen-induced arthritis model, they found COX-2 mRNA expression in inflamed
hind paw skin and the lumbar spinal cord, however, COX-2 expression was absent in the lumbar
L4 and L5 DRG (Dou, Jiao, Goorha, Raghow, & Ballou, 2004). Despite these findings, more
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recent studies have found that the expression of cyclooxygenases in the DRG is dependent on
pro-inflammatory conditions. The administration of interleukin-1β or carrageenan to rat hind
paws produced elevated COX-1 and COX-2 levels in TRPV-1 positive DRG nociceptive neurons
(Araldi et al., 2013). Collectively, this indicates the constitutive expression of COX-1 in DRG
neurons, with COX-2 upregulation under pro-inflammatory conditions.
These active eicosanoids recognize G -protein-coupled receptors on cell surfaces in an
autocrine or paracrine manner to induce downstream intracellular signaling pathways, which, in
the PNS, are involved in sensory pain mechanisms (Jang et al., 2020; Ricciotti & FitzGerald,
2011). Signaling cascades involving cyclic adenosine monophosphate (cAMP) and calcium
occur in the somatosensory system under inflammatory conditions, which can cause neuronal
hyperexcitability and contribute to an NP phenotype (Breyer, Bagdassarian, Myers, & Breyer,
2001).
In the PNS, prostaglandins initiate downstream signaling pathways in DRG sensory
neurons through prostaglandin receptors. PGE2 activates four PGE2-receptor subtypes
(PTGER1-4), all which have been detected in mouse and rat DRG neurons (Jang, Kim, &
Hwang, 2020; Oida et al., 1995). PTGER1 is associated with the G protein Gαq, and activation
of this receptor stimulates inositol 1,4,5-triphosphate production through phospholipase C. This
pathway triggers the release of intracellular calcium from the ER, and ultimately increases the
propagation of neuronal action potentials (Breyer, Bagdassarian, Myers, & Breyer, 2001;
Jabbour & Sales, 2004). PTGER2 and 4 are coupled with Gαs and amplifies cAMP production
through the activation of adenylyl cyclase, while, inversely, PTGER3 is responsible for reducing
cAMP levels and inhibiting adenylyl cyclase (Breyer et al., 2001; Jabbour & Sales, 2004). In
DRG neurons, studies primarily focus on PTGER4 activation. As previously mentioned,
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activation of this receptor by PGE2 induces the accumulation of cAMP. In a rat model of CFAinduced peripheral inflammation, PTGER4 expression is elevated in lumbar DRG neurons, and
when silencing PTGER4 by shRNA-mediated knockdown, this improves thermal and
mechanical hypersensitivity without disrupting normal pain thresholds (Lin et al., 2006). Upon
the administration of a PTGER4 antagonist, they also demonstrated the PGE2-mediated
suppression of TRPV1 when activated with capsaicin (Lin et al., 2006).
Along with PGE2, PGD2 has also been demonstrated to elicit cAMP accumulation in
sensory DRG neurons (Smith, Amagasu, Eglen, Hunter, & Bley, 1998). PGD2 activates two
receptor subtypes (PGDR1-2). PGDR1 stimulates adenylyl cyclase in the same manner as
PTGER2 and PTGER4, while PGDR2 has the same inhibitory actions as PTGER3 (Ebersberger
et al., 2011). Early studies have demonstrated that stimulation with a PTGDR1 antagonist
prevents PGD2-mediated Calcitonin-related gene peptide (CGRP) release in sensory neurons,
which is a neuropeptide involved in peripheral sensitization as well as NP (Jenkins, Feniuk, &
Humphrey, 2001). PTGDR1 activation also increases neuronal excitability by enhancing the
conductance of Nav1.8 sodium channels in sensory neurons (Ebersberger et al., 2011). In
connection with the inhibitory role of PTGDR2, activation of this receptor interferes with this
enhanced conduction initiated by PTGDR1, suggesting that PTGDR2 can function as a negative
regulator of PTGDR1 (Ebersberger et al., 2011).
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Figure 6. The Prostaglandin Synthesis Pathway in the DRG. Prostaglandins are
synthesized in response to physical, chemical, mitogenic, or inflammatory stimuli in
response to injury or damage that elicits a pro-inflammatory response. These stimuli
activate PLA2 to release arachidonic acid from the membrane phospholipids. Free
arachidonic acid is converted into the prostaglandin intermediate, Prostaglandin H2 by
COX-1 and/or COX-2. The tissue specific isomerases in the DRG, PTGES and PTGDS,
then convert Prostaglandin H2 into PGE2 and PGD2. These prostaglandins then activate
prostaglandin- specific receptors, notably involved in sensory pain mechanisms.
Lipid Rafts
Lipid rafts are highly dynamic, lipid-rich compartments of the cell membrane that
facilitate protein-protein and protein-lipid interactions for cellular signaling (Gianfrancesco,
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Paquot, Piette, & Legrand-Poels, 2018). The composition of these rafts is continuously changing,
regulating protein activity for downstream signaling processes due to the compartmentalization
of cellular signaling (Gianfrancesco et al., 2018). Cholesterol acts as a driving force in the
aggregation of lipid rafts, and disruptions in cellular cholesterol homeostasis not only alter the
physical characteristics of membrane fluidity, composition, and thickness, but the downstream
signaling processes (Korade & Kenworthy, 2008).
In the pathway of nociception, lipid rafts are involved in inflammation and NP in high
cholesterol conditions (Miller, Navia-Pelaez, Corr, & Yaksh, 2020). The role of lipid rafts and
pain processing is well documented in the context of the “inflammaraft,” which contains
receptors and adapter proteins that propagate inflammation (Miller et al., 2020). As previously
mentioned, TLR4 has been well documented to be activated in lipid rafts, and the activation of
ABCA1 by LXR reduces cholesterol in these rafts to inhibit the induction of downstream
inflammatory signaling through TLR4 (Ito et al., 2015).
In primary sensory neurons, Transient Receptor Potential Vanilloid 1 and Ankyrin 1
(TRPV1, TRPA1) cation channels are localized in lipid rafts, and are involved in pain processing
and inflammation (Horváth, Biró-Sütő, et al., 2020). When neuronal lipid rafts are disrupted
through cholesterol depletion, this decreases TRPV1 and TRPA1 stimulation evoking
mechanical allodynia in mice (Horváth, Biró-Sütő, et al., 2020). In a more recent report, the
authors demonstrate that lipid raft disruption by sphingomyelin depletion also reduces TRPV1
and TRPA1 activation, reducing nociceptive pain behavior in mice (Horváth, Payrits, et al.,
2020).
Despite these findings, little is known about how LXR activation in sensory neurons
specifically affects nociceptive and NP pathways, especially in the context of membrane
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remodeling and cholesterol homeostasis. As mentioned previously, LPCAT3 is a regulator of
membrane phospholipids and can modify membrane saturation and composition. Recent studies
have focused on the role of LPCAT3 in modulating the JNK pathway by c-Src recruitment to
lipid rafts. In hepatocytes stimulated with palmitate, siRNA mediated knockdown of LPCAT3
increases the concentration of phosphorylated c-Src, suggesting that the remodeling activity of
LPCAT3 is involved in its aggregation in lipid rafts to activate the JNK pathway (Rong et al.,
2013). As lipid rafts in neurons compartmentalize receptors involved in pain and nociception, the
lipid remodeling activity of LPCAT3 may be a potential target for mitigating neuronal
hyperexcitability and pain phenotypes in relationship to lipid dysfunction.

CHAPTER TWO
EXPERIMENTAL METHODS
Mice Strains
C57BL/6J (#000664) and RiboTag (#011029) mice were obtained from Jackson
laboratory (Maine, USA) and crossed with transgenic mice carrying a Cre recombinase driven by
the Scn10a promoter (Nav1.8::Cre mice) to generate wildtype and RiboTag+/+:Nav1.8Cre+/mice. All mice were housed in a 12:12h light/dark cycle and were used for experiments between
5 to 8 weeks of age.
Western Diet
Mice received either normal chow (NC) (Teklad LM-485) or WD (TD88137) that
contains 42%kcal from fat, 34% sucrose by weight, and 0.2% cholesterol for 12 weeks beginning
after weaning (Table 1) (Envigo, Indiana, USA).

Table 1. Nutritional Contents of Normal Chow and Western Diet. WD chow contains 42%
kcal from fat, 34% sucrose by weight, and 0.2% total cholesterol as opposed to the normal chow
diet that contains 5.8% kcal from fat without sucrose or cholesterol.
Contents

Normal Chow

Western Diet

Fat

5.8%

42%

Sucrose

0%

34%

Cholesterol

0%

0.2%

Transcript Enrichment of Nav1.8
DRG from RiboTag+/+:Nav1.8Cre+/- mice were extracted to perform organotypic
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cultures followed by RNA isolation. Immunoprecipitation followed by mRNA purification was
performed to isolate RNA associated with HA-tagged ribosomes of Nav1.8-expressing sensory
neurons. Harvested DRG were homogenized in homogenization buffer and centrifuged at
10,000xg for 10 min at 4C. Supernatant was removed, and the homogenate was incubated at 4C
with anti-HA antibody (Biolegend, #901513) at a 1:150 dilution for 4 hours on a tube rotator.
Then, samples were transferred to a tube containing magnetic beads (Pierce A/G magnetic beads,
California, USA) and incubated overnight at 4C on a tube spinner. The following day,
supernatant from the samples were collected and the magnetic beads were washed with high salt
buffer for 10 min at 4C on the spinner, repeated 3 times. After the final wash, lysis buffer
(RNeasy Micro Kit, QIAGEN, Maryland, USA) and β-mercaptoethanol (10ul/mL) was added for
mRNA elution. RNA was then isolated using RNeasy Micro Kit (QIAGEN, California, USA)
following manufacturer’s instructions and quantified with Nanodrop (Thermo Fisher,
Massachusetts, USA).
Primary DRG Neuronal Culture
DRG from mice were harvested in ice-cold advanced DMEM and axotomized.
Axotomized DRGs were then transferred and incubated in a collagenase A/trypsin mix
(1.25mg/mL each) for 30 min. The digested DRG were then homogenized using fire polished
glass pipettes and spun for 3 min at 3000xg. Supernatant was then removed, and cells were
resuspended in DMEM/F12 containing 10% FBS. Cells were plated onto poly-l-lysine treated
12-well plates (with or without coverslips) and maintained in a 37C and 5%CO2 incubator for 4
days with media changes supplemented with Ara-C (20uM) to inhibit non-neuronal cell
replication. Media was then replaced with DMEM/F12 containing 2.5% FBS overnight before
treatment. Following serum depletion, cells were treated with 250uM palmitate for 24 hours,
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following with vehicle or 15uM GW3965 in low serum media for another 24 hours. RNA was
extracted using Acturus PicoPure RNA Extraction Kit (Applied Biosystems, California, USA).
Immunofluorescence Staining
Primary DRG neuronal cultures were performed as described above. After treatment,
cells were washed with cold PBS and incubated in 4%PFA for 15 min. Cells were again washed
with PBS and permeabilized in 1x PBS containing 0.2% Triton X for 5 min. Then,
permeabilization solution was replaced with blocking buffer containing 1x PBS, 0.2% Triton X,
and 3%BSA, and incubated for 1 hr. Samples were incubated with β-tubulin III primary antibody
overnight, then washed with PBS. Wells were then incubated with the secondary antibody for 1
hr, following co-staining with DAPI. Coverslips were mounted on slides for imaging.
Quantitative PCR
100ng of RNA from DRG cultures was converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, California, USA). For all genes of
interest, qPCR was performed using Sybr green-based assay (Roche, Indiana, USA) and IDT
primers (IDT technologies, Iowa, USA).
Prostaglandin Quantification
Harvested DRG were transferred to tubes prefilled with zirconium oxide beads with icecold PBS. The samples were homogenized using a Bullet Blender (Next Advance, New York,
USA) at speed 8 for 5 min. Tissue homogenate was collected and centrifuged at 1000xg for 20
min at 4C. The supernatant was then collected and used for the ELISA assay. PGD2 levels in the
DRG were evaluated using Prostaglandin D2-MOX ELISA Kit (Cayman Chemical, Michigan,
USA) following the manufacturer’s instructions. The same amount of tissue and DRGs were
used per sample in the ELISA assay.
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Lipidomics
Primary DRG cultures were performed as described above. Cells were treated with
vehicle or 15uM GW3965, with 5 biological replicates per treatment. Lipidomics was performed
by UCLA Lipidomics Core using modified Bligh and Dyer lipid extraction for lipidomics
analysis using the Sciex Lipidyzer Mass Spectrometry Platform. Samples were analyzed on the
Sciex Lipidyzer Platform for quantitative measurement of 1100 lipid species across 13 lipid subclasses. Data analysis was performed on Lipidyzer software. Quantitative values were
normalized to the number of cells in the provided sample using Gene-Chip Mouse Gene 430.2
Arrays (Affymetrix, Santa Clara, CA).
RNA Sequencing
RNA was extracted from DRG of NC- or WD-fed mice or from primary DRG neurons
cultured as described above and treated with vehicle or 15uM GW3965. Two biological
replicates were used for each group. Total RNA was quantified by Qubit and quality assessed
using Total RNA Pico Chip. RNA samples that passed this quality check were used as input for
library construction. Samples were sequenced at Northwestern University.
Statistical Analysis
Statistical analysis for gene expression and ELISA were done in GraphPad Prism 9.
All data are represented as mean ± SEM. Comparisons between experimental treatments were
performed using Two-sample t-test. p<0.05 was considered statistically significant. Schematic
images were created using BioRender.
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CHAPTER THREE
RESULTS
Lipid Gene Profiling in Nav1.8 DRG Sensory Neurons of NC and WD-Fed Mice
The DRG contains various cell types, including glial cells, epithelial cells, and
macrophages, we use RiboTag+/+:Nav1.8Cre+/- mice to isolate the mRNA in translation located
in Nav1.8 expressing sensory neurons. Nav1.8 is expressed in 90% of nociceptors, and is
involved neuropathic and inflammatory pain pathways, contributing to the hyperexcitability of
neurons in response to sensory stimuli (Stirling et al., 2005; Strickland et al., 2008; Xiao et al.,
2019). This tissue-specific Ribotag mouse encodes a ribosomal protein gene (Rpl22), containing
a floxed c-terminal Exon followed by an identical exon tagged with HA. With the Nav1.8 Cre
mouse, the HA-tagged Exon is activated and incorporated into actively translating ribosomes.
(Sanz et al., 2009) (Figure 7).
Using co-immunoprecipitation techniques, we utilize an anti-HA antibody to specifically
pull-down HA- tagged ribosomes in translation in Nav1.8 expressing neurons. We then
precipitate the HA- tagged ribosomes and associated mRNA from these Nav1.8 positive neurons
in the IP Sample. We performed RNA sequencing on DRG from NC- and WD-fed
RiboTag+/+:Nav1.8Cre+/- mice. Of LXR target genes in the DRG, only LDLRand LPCAT3
were detectable, with no significant differences in read counts between NC- and WD-fed mice
(Figure 8). We have shown that in our WD model, mice develop the characteristics of MetS and
NP. In terms of lipid metabolism in the DRG, FASN issignificantly downregulated in WD-fed
mice, suggesting the downregulation of lipogenesis in the DRG, due to diet-induced lipid
overload. Interestingly, we also found that PTGDS, responsible for PGD2 synthesis, is
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significantly upregulated in WD-fed mice, suggesting that lipid dysregulation in our model may
indirectly affect the prostaglandin synthesis pathway. PTGES, however, is undetectable in
sensory DRG neurons regardless of diet. As previously mentioned, there is conflicting evidence
surrounding the modulation of prostaglandin synthesisin the DRG, but specifically, in our model,
we confirm that PTGDS is detectable in Nav1.8 expressing sensory neurons.

Figure 7. Generation of the Sensory Neuron Specific Ribotag Mouse. (A) Nav1.8 Cre mice
were used to generate RiboTag+/+:Nav1.8Cre+/- mice. This ribotag mouse has a ribosomal
protein gene (Rpl22) with a floxed see terminal Exon followed by an identical exon tagged with
HA. When crossed with Nav1.8 cre mice, the HA-tagged Exon is activated and incorporated into
actively translating ribosomes.
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Figure 8. Genes Regulated in Nav1.8 Sensory Neurons of NC- and WD-Fed Mice. (A)
mRNAread counts in primary Nav1.8 DRG neurons in NC- and WD-fed mice (n=2 per
treatment).FDR-adjusted p-values, ***p<0.0005, ****p<0.0001. Values are mean ± SEM.
Genes regulated by LXR activation in Nav1.8 DRG Sensory Neurons
Using Tomato+/+:RiboTag+/+:Nav1.8Cre+/- mice, specifically, the cre-driven tomato
reporter allows us to confirm cre expression for further ex vivo studies. Neurons in culture are
supplemented with Ara-C, an S phase blocker that prevents the differentiation of replicative cell
types ex vivo. Neurons are also co-stained with β-actin, which is a highly conserved protein in
extracellular support structures and axonal growth. (Figure 9A).
We then performed RNA sequencing on primary DRG neurons treated with vehicle or
15uM GW3965 from RiboTag+/+:Nav1.8Cre+/- mice (Figure 9B). Upon LXR activation,
LDLR, responsible for LDL uptake, was significantly downregulated in the DRG. ABCA1,
which is responsible for cholesterol efflux, was not only largely detectable in the DRG compared
to other LXR target genes but was significantly upregulated upon LXR activation. LPCAT3,
demonstrated to be involved in phospholipid remodeling, had the lowest read count out of all
detectable LXR target mRNA transcripts in the DRG, but was significantly upregulated upon
LXR activation. This demonstrates that not only are these LXR target genes present in the DRG
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but are regulated by LXR activation with the synthetic agonist GW3965. Through this
upregulation of LXR target genes, LXR regulates multiple aspects of lipid metabolism, including
lipid transport and remodeling.
To understand whether this modulation of lipid homeostasis by LXR is occurring under
high saturated fat conditions, we performed primary cultures of DRG neurons and treated cells
with 250uM of palmitate followed by vehicle or 15uM GW3965. As previously mentioned,
palmitate is a saturated fatty acid that is used to mimic high fat conditions ex vivo. We
observed a significant increase in LXR target genes in primary neurons, including ABCA1,
LPCAT3, and IDOL, which are all involved in lipid homeostasis upon LXR activation (Figure
10). Interestingly, there were no significant changes in the relative expression of LDLR
between vehicle and GW3965 under saturated fat conditions.
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A

B

Figure 9. Genes Regulated by LXR Activation in Nav1.8 Sensory Neurons. (A) Imaging
of primary DRG neurons isolated from Tomato+/+:RiboTag+/+:Nav1.8Cre+/- mice. Cells
weretreated with Ara-C to inhibit replicative cells in culture. (blue, DAPI/nuclei; green, βTubulin III; red, Tomato/Nav1.8) (scale bar, 50μM). (B) mRNA read counts of LXR target
genes in RiboTag+/+:Nav1.8Cre+/- mice treated with either vehicle or GW3965 (n=2 per
treatment). FDR-adjusted p-values, ***p<0.0005, ****p<0.0001. Values are mean ± SEM.
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Figure 10. LXR Activation Upregulates Genes involved in Lipid Homeostasis under High
Fat Conditions Ex Vivo. mRNA levels of LXR target genes in primary DRG neurons treated
with250μM palmitate followed by vehicle or 15μM GW3965. Two-sample t-test,
*p<0.05,***p<0.0005. Values are mean ± SEM.
PGD2 Production Increases in Tissues of the Nociceptive Pathway of WD-Fed Mice
Given the upregulation of PGDS in WD-fed mice, we then wanted to determine the
bioavailableconcentration of PGD2 in the nociceptive pathway, including the spinal cord, DRG,
and sciatic nerve of NC- and WD-fed mice (Figure 11). Due to the instability of PGD2 once
synthesized, we converted PGD2 into Prostaglandin D2 – Methylmoxime (PGD2-MOX) to
prevent further chemical degradation for analysis. PGD2-MOX was detectable in all samples,
mostly in the spinal cord and DRG. While all tissues demonstrate an increase in PGD2-MOX
concentrations, there was a significant increase in the spinal cord and DRG of WD-fed mice.
PGDS is Downregulated in Sensory Neurons of the DRG upon LXR activation
We determined that PGDS is upregulated in WD-fed mice and that the concentration of PGD2
increases in the spinal cord and DRG of our model. As previous studies have reported that
LPCAT3 is responsible for phospholipid remodeling and the insertion of arachidonic acid into
the membrane, we hypothesized that LXR activation may modulate the synthesis of
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prostaglandins in the DRG. We performed primary DRG cultures and treated cells with palmitate
followed by vehicle or GW3965 as previously described (Figure 12). Upon LXR activation in
high fat conditions, PTGDS was significantly down regulated in the DRG, suggesting that LXR
may be modulating prostaglandin synthesis indirectly through the modulation of lipid
metabolism under high fat conditions. COX-2 the inducible isoform of cyclooxygenase in the
prostaglandin synthesis pathway, had no significant difference in mRNA levels in the DRG.
Because COX-2 is regulated by multiple inflammatory pathways, it is possible that the high fat
conditions in culture promote the persistent upregulation of COX-2, while changing other
enzymes of the prostaglandin synthesis pathway.

Figure 11. PGD2 Production Increases in Various Tissues of WD-Fed Mice. Levels of
methylmoximated PGD2 in the spinal cord, whole DRG (n=6/mice), and sciatic nerve (SN) from
mice fedeither NC (n=6) or WD (n=7) for 12 weeks. Two-sample t-test, *p<0.05.Values are
mean ± SEM.
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Figure 12. PTGDS is Downregulated in Palmitate Treated Primary DRG Neurons upon
LXR Activation. mRNA levels of PTGDS and COX-2 in primary DRG neurons treated with
250μM palmitate followed by vehicle or 15μM GW3965. Two-sample t-test, *p<0.05. Values
are mean± SEM.
LXR Activation in the DRG is Involved in Modulating Neuronal Lipid Composition
As previously discussed, LPCAT3 is responsible for phospholipid remodeling and the
incorporation of polyunsaturated fatty acids in membrane phospholipids. To determine whether
LXR activation is modulating membrane composition, we characterized the lipid class and
cholesterol ester species of primary DRG neurons treated with GW3965 using lipidomics.
While lipidomics characterizes lipids from the whole neuron, the membrane, and most
importantly, lipid rafts, largely make up the lipid content of neurons. As previously mentioned,
the neuronal membrane is largely composed of phospholipid species, mostly of
phosphatidylcholine and phosphatidylethanolamine. In primary DRG neurons treated with
GW3965, LXR modulates the concentration of lipid subclasses, most notably increasing levels of
phosphatidylcholine in cultured neurons (Figure 13A). As we have previously described,
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LPCAT3 is involved in the modulation of phospholipids and may explain the increase in the
concentration of phospholipid subclasses. Cholesterol esters in membranes are largely
responsible for the aggregation of lipid droplets and membrane raft dynamics. LXR activation
increases various cholesterol ester concentrations in the DRG (Figure 13B). As we have
previously described, LPCAT3 is responsible for the insertion of arachidonic acid (20:4) and
linoleic acid (18:2) into membrane phospholipids. Interestingly, Cholesteryl arachidonate (CE
20:4) and cholesteryl linoleate (CE 18:2), which are derived from arachidonic acid and linoleic
acid, increase in the DRG upon LXR activation. Suggesting the incorporation of these acids in
the membrane by LPCAT3.
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Figure 13. LXR Modulates the Composition of Lipids in the DRG. (A)The concentrationof
various cholesterol ester species in primary DRG neurons treated with vehicle or 15μMGW3965.
(B) The concentration of various cholesterol ester species in primary DRG neurons treated with
vehicle or 15μM GW3965. Values are mean ± SEM Concentrations are reported as nmoles per
10^7 cells (n = 5 replicates per group). Two-sample t-test, *p<0.05, **p<0.005, ***p<0.0005.
Values are mean ± SEM.

CHAPTER 4
DISCUSSION
The previous results were gathered in an attempt to understand the role of LXR in
attenuating inflammation and pain involved in CSPN via lipid regulation in the DRG.
Interestingly, in our ex vivo studies of sensory DRG neurons, we did not see a change in mRNA
levels of LDLR. Some studies suggest that the degradation of LDLR by LXR-activated IDOL
occurs under chronic intracellular lipid excess, and in some reports, LXR activation may even
induce the expression of LDLR (Ishimoto et al., 2006; Zhang, Reue, Fong, Young, & Tontonoz,
2012). RNA sequencing data of Nav1.8 primary neurons treated with GW3965 demonstrate the
downregulation of LDLR, however, the high fat conditions and treatment protocol may affect the
regulation of the LDLR and IDOL pathway. Ideally, we would also repeat experiments using the
vehicle control for palmitate with and without GW3965 to determine if this effect may be due to
the ex vivo high fat conditions. If the regulation of LDLR and IDOL is dependent on chronic
lipid dysfunction, it would be difficult to determine in primary DRG neurons as long-term stress
reduces cell viability in culture.
We have demonstrated that LXR activation does modulate lipid metabolism in the DRG,
and that prostaglandins, which are key mediators of inflammation, are upregulated in our WD
model for MetS and NP. Because inflammation, along with other perturbations in lipid
homeostasis, is associated with CSPN and NP, the progress gained in this study will allow us to
further test the hypothesis that LXRs, specifically the target gene LPCAT3, play a role in
phospholipid remodeling to reduce the availability of arachidonic acid in the DRG for
36
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prostaglandin synthesis. The significant increase in cholesterol ester composition of the DRG,
more specifically linoleic acid and arachidonic acid-containing species, suggests that changes in
membrane lipid composition may be due to the upregulation of LPCAT3. In future studies, we
would like to specify that LPCAT3 is the culprit for reducing prostaglandin synthesis in sensory
neurons by reducing the availability of arachidonic acid, and that this overall pathway is
regulated by LXR. This could be done by either repeating experiments with LPCAT3 knockout
mice or siRNA mediated silencing of LPCAT3 in primary DRG neurons. In connection with
lipid raft microdomains, we are also attempting to visualize the lipid rafts in primary DRG
neurons upon treatment with GW3965 and palmitate.
We have demonstrated that PGD2 synthesis is upregulated in the nociceptive pathway,
however, due to time constraints, we were unable to treat our WD model with the LXR agonist
GW3965. This would allow us to study the effects of GW3965 on PGD2 synthesis in our model
for MetS and NP, as well as repeat ELISA experiments on neuronal tissues with LXR activation.
Ideally, we would also demonstrate the effects of LXR activation on PTGDS using the vehicle
control for palmitate to determine if this regulation of PTGDS is reliant on inflammation due to
palmitate treatment. To confirm whether or not LXR activation is the culprit for this attenuation,
an LXR knockout model would be useful when repeating these experiments. To determine
whether LPCAT3 is responsible for reducing the availability of arachidonic acid in the
membrane, silencing LPCAT3 for ex vivo studies of sensory neurons will help us determine
whether this LXR target gene alone is affecting prostaglandin synthesisin the DRG, or if this is
mediated by other neuronal pathways.
These results serve as preliminary data to understand how inflammation affects NP.
While the molecular mechanisms underlying prostaglandins and nociception have been
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documented, there are limited studies documenting prostaglandins in relationship to NP, as
models used to study its mechanisms involve surgical procedures (such as sciatic nerve
transection or spinal nerve ligation) that can trigger inflammation unrelated to neuronal injury
(Ho Kim & Mo Chung, 1992; Zhu & Eisenach, 2003). NP studies document the upregulation of
cyclooxygenases and prostaglandins in these models, however, peripheral nerve damage may not
be the sole culprit for these results (Zhu & Eisenach, 2003). While obesity and MetS are
considered to be acute inflammatory conditions, studying NP using clinically relevant models
such as WD-fed mice can offer insight on the relationship between prostaglandins and
neuroinflammation in the context of MetS-associated PN.
In future studies regarding prostaglandin synthesis in the DRG, we must characterize the
pain phenotype in connection with LXR activation in the nociceptive pathway with behavioral
pain studies. Given that LXR activation in the DRG is altering membrane composition, and that
lipid rafts are critical for nociceptive signaling, further investigations about the neurobiology
behind lipid remodeling and ectopic signaling needs to be done in our WD model in relationship
to prostaglandin synthesis in the nociceptive pathway. Other studies have demonstrated changes
in nociceptive signaling in high-fat diet mice using calcium imaging and patch clamp recordings.
This may be useful in connecting prostaglandin synthesis with ectopic signaling and NP. As
previously mentioned, TRPV1 and TRPA1, which are receptors involved in pain signaling and
are localized in lipid rafts, may be potentially affected by cholesterol disruption due to LXR
activation. Understanding how pain receptors are affected by lipid dysfunction in association
with MetS-associated neuropathy and NP may be useful in determining how LXR indirectly
affects downstream pain pathways in the PNS.
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We primarily study sensory neurons of the DRG, and LXR is expressed in non-neuronal
cell types of the PNS. In the context of inflammation, LXR has been well documented to
suppress pro-inflammatory pathways in macrophages. Little is understood about how LXR
activation in non-neuronal cell types affect sensory neurons and nociception. Understanding this
relationship may reveal how the activation and repression of LXR target genes collectively
contribute to neuronal injury and NP.
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